Tectonic Therapeutic | AVRO
Stock Price
48.10
Daily Change
3.21 7.15%
Monthly
39.38%
Yearly
217.99%
Q4 Forecast
42.49


Peers Price Chg Day Year Date
Celltrion 173,500.00 -200.00 -0.12% 0.35% Nov/22
Cspc Pharmaceutical 5.09 -0.10 -1.93% -27.80% Nov/22
Sino Biopharmaceutical 3.30 -0.08 -2.37% -14.95% Nov/22
Takeda 4,113.00 -8.00 -0.19% -2.14% Nov/22
Zhangzhou Pientzehuang Pharmaceutical 236.00 -9.48 -3.86% -8.14% Nov/22
Kangmei Pharma 2.31 -0.09 -3.75% 20.31% Nov/22
Adcock Ingram Holdings 6,729.00 -51.00 -0.75% 22.12% Nov/22
Alnylam Pharmaceuticals 244.89 -1.91 -0.77% 50.31% Nov/22
Ecofibre 0.04 0 0% -67.69% Nov/21
Gilead Sciences 90.01 0.40 0.45% 19.41% Nov/22
Knight Therapeutics 5.29 -0.01 -0.19% 0.57% Nov/22
Ionis Pharmaceuticals 34.01 0.07 0.21% -31.75% Nov/22
MacroGenics 3.24 0.03 0.93% -56.80% Nov/22
Dianthus Therapeutics 22.34 2.07 10.21% 90.94% Nov/22
Malin Corporation 6.05 0 0% 38.76% Nov/22
Medical Developments International 0.42 -0.01 -1.18% -46.84% Nov/22
Neuren Pharmaceuticals 12.36 -0.07 -0.56% -16.71% Nov/22
Organigram Holdings 2.15 0.05 2.14% 25.73% Nov/22
Pfizer 25.66 0.56 2.23% -15.87% Nov/22
Pharma Mar 73.50 0.40 0.55% 90.91% Nov/22
Qiagen NV 41.05 0.83 2.05% 9.57% Nov/22
Roche Holding 254.30 3.20 1.27% 6.69% Nov/22
Laboratorios Farma 63.00 1.15 1.86% 16.99% Nov/22
Sanofi 93.17 2.30 2.53% 8.04% Nov/22
Sarepta Therapeutics 114.23 3.73 3.38% 37.84% Nov/22
Sartorius 211.10 7.10 3.48% -26.19% Nov/22
Tilray 1.88 0.04 2.17% -22.63% Nov/22

Tectonic Therapeutic Inc. traded at $48.10 this Friday November 22nd, increasing $3.21 or 7.15 percent since the previous trading session. Looking back, over the last four weeks, Tectonic Therapeutic gained 39.38 percent. Over the last 12 months, its price rose by 217.99 percent. Looking ahead, we forecast Tectonic Therapeutic Inc. to be priced at 42.49 by the end of this quarter and at 40.94 in one year, according to Trading Economics global macro models projections and analysts expectations.

Tectonic Therapeutic Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.